(0.18%) 5 164.25 points
(0.15%) 38 891 points
(0.14%) 18 026 points
(1.14%) $79.00
(-0.14%) $2.14
(0.79%) $2 326.80
(2.50%) $27.36
(1.00%) $974.95
(0.00%) $0.929
(-0.30%) $10.84
(-0.28%) $0.795
(-0.13%) $91.33
3 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...
Stats | |
---|---|
今日成交量 | 435 400 |
平均成交量 | 342 822 |
市值 | 295.61B |
EPS | ¥0 ( 2024-02-08 ) |
下一个收益日期 | ( ¥39.17 ) 2024-05-09 |
Last Dividend | ¥57.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 12.24 |
ATR14 | ¥2.72 (0.06%) |
音量 相关性
Nippon Shinyaku Co., Ltd. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Nippon Shinyaku Co., Ltd. 相关性 - 货币/商品
Nippon Shinyaku Co., Ltd. 财务报表
Annual | 2022 |
营收: | ¥144.18B |
毛利润: | ¥88.20B (61.17 %) |
EPS: | ¥338.70 |
FY | 2022 |
营收: | ¥144.18B |
毛利润: | ¥88.20B (61.17 %) |
EPS: | ¥338.70 |
FY | 2022 |
营收: | ¥137.48B |
毛利润: | ¥87.29B (63.49 %) |
EPS: | ¥370.97 |
FY | 2021 |
营收: | ¥121.89B |
毛利润: | ¥71.93B (59.02 %) |
EPS: | ¥307.37 |
Financial Reports:
No articles found.
Nippon Shinyaku Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥57.00 (N/A) |
¥0 (N/A) |
¥57.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥5.00 | 2001-03-27 |
Last Dividend | ¥57.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 45 | -- |
Total Paid Out | ¥829.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.77 | |
Div. Directional Score | 9.75 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8338.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7723.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6882.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6255.T | Ex Dividend Junior | 2023-08-30 | Sporadic | 0 | 0.00% | |
4972.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4185.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3382.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
2453.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9386.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.164 | 1.500 | 6.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0974 | 1.200 | 6.75 | 8.10 | [0 - 0.3] |
returnOnEquityTTM | 0.117 | 1.500 | 9.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.331 | -1.000 | 6.69 | -6.69 | [0 - 1] |
currentRatioTTM | 5.92 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.17 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.11 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00826 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 264.20 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00953 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.646 | 1.000 | 2.57 | 2.57 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.226 | 1.000 | 7.47 | 7.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.59 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.593 | 0.800 | 9.38 | 7.50 | [0.5 - 2] |
Total Score | 13.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 12.25 | 1.000 | 8.86 | 0 | [1 - 100] |
returnOnEquityTTM | 0.117 | 2.50 | 9.88 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.83 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.331 | 1.500 | 6.69 | -6.69 | [0 - 1] |
pegRatioTTM | -2.01 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.147 | 1.000 | 8.81 | 0 | [0.1 - 0.5] |
Total Score | 5.77 |
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。